Tarsus Pharmaceuticals, Inc. financial data

Symbol
TARS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
15440 Laguna Canyon Road, Irvine, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 669 % -49.1%
Quick Ratio 6.19 %
Debt-to-equity 42.2 % +82.1%
Return On Equity -55.9 % +5.55%
Return On Assets -39.3 % +18.2%
Operating Margin -108 % +86.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.2M shares +15.5%
Common Stock, Shares, Outstanding 38.2M shares +15.4%
Entity Public Float 460M USD +155%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 38.4M shares +25.3%
Weighted Average Number of Shares Outstanding, Diluted 38.4M shares +25.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 130M USD +802%
Research and Development Expense 49.8M USD +5.92%
General and Administrative Expense 57.9M USD +91%
Costs and Expenses 73.3M USD +71.2%
Operating Income (Loss) -141M USD -23.6%
Nonoperating Income (Expense) 6.26M USD +1.23%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -134M USD -24.9%
Earnings Per Share, Basic -3.79 USD/shares 0%
Earnings Per Share, Diluted -3.79 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 176M USD -22.3%
Marketable Securities, Current 141M USD +596%
Accounts Receivable, after Allowance for Credit Loss, Current 29.2M USD +444%
Inventory, Net 2.85M USD +18873%
Assets, Current 357M USD +37.7%
Property, Plant and Equipment, Net 2.39M USD +48.3%
Operating Lease, Right-of-Use Asset 1.8M USD -10.4%
Intangible Assets, Net (Excluding Goodwill) 8.57M USD +116%
Other Assets, Noncurrent 888K USD -29.1%
Assets 376M USD +40.2%
Employee-related Liabilities, Current 11.3M USD +43.4%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 65.9M USD +183%
Operating Lease, Liability, Noncurrent 1.24M USD -25.6%
Other Liabilities, Noncurrent 1.24M USD -27.5%
Liabilities 139M USD +154%
Accumulated Other Comprehensive Income (Loss), Net of Tax 346K USD
Retained Earnings (Accumulated Deficit) -337M USD -66.3%
Stockholders' Equity Attributable to Parent 237M USD +11.1%
Liabilities and Equity 376M USD +40.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.8M USD -72%
Net Cash Provided by (Used in) Financing Activities 109M USD +2070%
Net Cash Provided by (Used in) Investing Activities -102M USD -1005%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 38.2M shares +15.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -31.2M USD -452%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 176M USD -22.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 868K USD +46.4%
Deferred Tax Assets, Valuation Allowance 60.3M USD +139%
Deferred Tax Assets, Gross 61M USD +141%
Operating Lease, Liability 1.87M USD -10.4%
Depreciation 710K USD +34.2%
Payments to Acquire Property, Plant, and Equipment 174K USD -48.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -134M USD -24.5%
Lessee, Operating Lease, Liability, to be Paid 2.27M USD -12.7%
Property, Plant and Equipment, Gross 4.18M USD +57.2%
Operating Lease, Liability, Current 631K USD +49.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 994K USD +26%
Lessee, Operating Lease, Liability, to be Paid, Year One 961K USD +37.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 235K USD -38.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 83K USD -89.8%
Deferred Tax Assets, Operating Loss Carryforwards 25.9M USD +287%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.93M USD +15.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Additional Paid in Capital 574M USD +37.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 433K USD
Deferred Tax Assets, Net of Valuation Allowance 733K USD +496%
Share-based Payment Arrangement, Expense 25.9M USD +43.7%
Interest Expense 3.65M USD +42%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%